A multicenter, real-world experience with recombinant FXIII for the treatment of patients with FXIII deficiency: from pharmacokinetics to clinical practice. The Italian FXIII Study.

Ezio Zanon,Samantha Pasca,Gianluca Sottilotta,Angelo C Molinari,Antonietta Ferretti,Patrizia Di Gregorio,Berardino Pollio,Michele Pizzuti,Lucia Dora Notarangelo,Chiara Biasoli,Piergiorgio Cojutti,Federico Pea,Paolo Simioni,Flora Peyvandi

Blood transfusion = Trasfusione del sangue（2022）

Cited 1|Views13

No score

Abstract

Efficacy and safety of rFXIII were proven in all patients. The dosage and infusion timing for the treated patients sometimes differed to those reported in the MENTOR pivotal studies, thus underlying the importance of tailored management in a real-world scenario.

Translated text

Key words

fxiii deficiency,recombinant fxiii,italian fxiii study,pharmacokinetics,treatment,real-world

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined